CVRx, Inc.

NasdaqGS CVRX

CVRx, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -54.29 M

CVRx, Inc. EBITDA is USD -54.29 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -33.94% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

CVRx, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -40.53 M, a 0.22% change year over year.
CVRx, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -40.62 M, a -22.16% change year over year.
CVRx, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -33.25 M.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqGS: CVRX

CVRx, Inc.

CEO	Mr. Kevin Hykes
IPO Date	June 30, 2021
Location	United States
Headquarters	9201 West Broadway Avenue
Employees	200
Sector	Health Care
Industries Pharmaceuticals Medical Instruments

Description

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Key trends

Past 5 years